Li Jiashan, Liang Siying, Miao Yan, Du Xiaoyu, Han Meiyan, Zhao Wei, Jiang Nan, Zhou Yingchao
Genetic Testing Center, Women and Children's Hospital Affiliated to Qingdao University, Qingdao, Shandong 266034, China.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2025 Jul 10;42(7):869-882. doi: 10.3760/cma.j.cn511374-20250623-00382.
To explore the genetic etiology of fetal skeletal dysplasia using whole exome sequencing (WES) and copy number variation sequencing (CNV-seq) techniques, and the feasibility of using WES as the first-tier method for such fetuses.
Seventy four fetuses with skeletal dysplasia detected by prenatal ultrasound at the Genetic Testing Center of the Women and Children's Hospital Affiliated to Qingdao University from January 2020 to August 2024 were selected as the study subjects. Fetal muscle and peripheral blood samples of the pregnant women and their spouses were collected and subjected to WES analysis. CNV-seq was carried out on all fetal muscle tissue samples. And the results were compared with the CNVs indicated by WES. Genetic etiologies were analyzed across different subtypes of skeletal dysplasia. And the feasibility of using WES as the first-tier genetic test for similar fetuses was assessed, in addition with a systematic cost-effectiveness analysis. This study was approved by the Medical Ethics Committee of the Hospital (Ethics No.: QFELL-YJ-2024-201).
A total of 50 fetuses were diagnosed, which yielded a diagnostic rate of 67.57%. These included 6 chromosomal aneuploidies, 4 chromosomal CNVs and 40 monogenic disorders. The monogenic diseases had involved 46 variant sites in 23 pathogenic genes, among which 12 were unreported previously, including MYH3: c.735T>C, ALPL: c.1324C>T, NEK9: c.1973G>A, MAGEL2: c.2024_2025del, LMBR1: c.423+4914A>C, NEB: c.21273_21276del, COL1A1: c.2651G>C and c.2758G>C, ASPM: c.2473delinsGA, TBX5: c.704G>A, DYNC2H1: c.10893del, and DYNC2I2: c.1270C>T. Substantial concordance was reached between WES-derived CNV calls and CNV-seq findings. No clinically significant CNV was exclusively detected by CNV-seq. Cost-effectiveness modeling demonstrated that implementing WES as the first-tier genetic testing method could reduce the total expenditure when WES unit cost remained below 6.4 folds that of the CNV-seq.
Genetic variants including single nucleotide variations (SNV) of monogenic disorders, chromosomal aneuploidies and genomic CNVs are important causes for fetal skeletal dysplasia. WES is an accurate and efficient method for analyzing the etiology of fetal skeletal dysplasia, particularly in those with a family history of similar phenotype or maternal history of adverse pregnancies.
运用全外显子组测序(WES)和拷贝数变异测序(CNV-seq)技术探索胎儿骨骼发育不良的遗传病因,以及将WES用作此类胎儿一级检测方法的可行性。
选取2020年1月至2024年8月在青岛大学附属妇女儿童医院遗传检测中心经产前超声检查发现骨骼发育不良的74例胎儿作为研究对象。采集胎儿肌肉及孕妇及其配偶的外周血样本,进行WES分析。对所有胎儿肌肉组织样本进行CNV-seq检测,并将结果与WES显示的拷贝数变异(CNV)进行比较。分析不同亚型骨骼发育不良的遗传病因。评估将WES用作类似胎儿一级基因检测的可行性,并进行系统的成本效益分析。本研究经医院医学伦理委员会批准(伦理编号:QFELL-YJ-2024-201)。
共诊断出50例胎儿,诊断率为67.57%。其中包括6例染色体非整倍体、4例染色体CNV和40例单基因疾病。单基因疾病涉及23个致病基因中的46个变异位点,其中12个此前未报道,包括MYH3:c.735T>C、ALPL:c.1324C>T、NEK9:c.1973G>A、MAGEL2:c.2024_2025del、LMBR1:c.423+4914A>C、NEB:c.21273_21276del、COL1A1:c.2651G>C和c.2758G>C、ASPM:c.2473delinsGA、TBX5:c.704G>A、DYNC2H1:c.10893del和DYNC2I2:c.1270C>T。WES得出的CNV结果与CNV-seq结果高度一致。CNV-seq未单独检测到具有临床意义的CNV。成本效益模型表明,当WES单位成本低于CNV-seq的6.4倍时,将WES用作一级基因检测方法可降低总支出。
包括单基因疾病的单核苷酸变异(SNV)、染色体非整倍体和基因组CNV在内的遗传变异是胎儿骨骼发育不良的重要原因。WES是分析胎儿骨骼发育不良病因的准确且高效的方法,尤其适用于有类似表型家族史或不良妊娠母胎史的胎儿。